News & Updates Press Release Van Agens 3/8/24 Press Release Van Agens 3/8/24 Promontory Therapeutics Completes Enrollment of Phase 2 Trial of PT-112 in Late-Line Patients with Metastatic Castration-Resistant Prostate Cancer Read More Press Release Van Agens 11/4/23 Press Release Van Agens 11/4/23 Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects Read More Press Release Van Agens 10/14/23 Press Release Van Agens 10/14/23 Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read More Press Release Van Agens 10/5/23 Press Release Van Agens 10/5/23 Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From the National Cancer Institute, Demonstrating PT-112's Immune Activation in Thymic Epithelial Tumors Read More Press Release Van Agens 9/29/23 Press Release Van Agens 9/29/23 Promontory Therapeutics Selected as the First International Biotech Company Member of the Paris-Saclay Cancer Cluster Read More Press Release Van Agens 7/27/23 Press Release Van Agens 7/27/23 The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup" Read More Press Release Van Agens 7/20/23 Press Release Van Agens 7/20/23 Promontory Therapeutics Expands Phase 2 Trial of PT-112 in Metastatic Castrate-Resistant Prostate Cancer to France Read More Press Release Van Agens 6/2/23 Press Release Van Agens 6/2/23 Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting Read More Press Release Van Agens 5/31/23 Press Release Van Agens 5/31/23 Promontory Therapeutics to Participate in Business Development Strategies Panel at the Sachs 9th Annual Immuno-Oncology Innovation Forum Read More Press Release Van Agens 2/16/23 Press Release Van Agens 2/16/23 Promontory Therapeutics Presents Phase 2 Trial in Progress for PT-112 in Prostate Cancer at 2023 ASCO Genitourinary Cancers Symposium Read More Press Release Van Agens 12/8/22 Press Release Van Agens 12/8/22 Promontory Therapeutics Presents Safety and Efficacy Data of PT-112 in Combination with PD-L1 Inhibition in Treatment of Advanced Non-Small Cell Lung Cancer at ESMO I-O 2022 Read More Press Release Van Agens 11/28/22 Press Release Van Agens 11/28/22 Promontory Therapeutics Appoints Stan Musial as Chief Financial Officer Read More Press Release Van Agens 11/11/22 Press Release Van Agens 11/11/22 Promontory Therapeutics Presents on the Immunological Effects of PT-112 in Cancer Cell Mitochondria at SITC 2022 Read More Press Release Van Agens 11/3/22 Press Release Van Agens 11/3/22 Promontory Therapeutics Awarded “Cancer Immunology Solution of the Year” in 2022 BioTech Breakthrough Awards Program Read More Press Release Van Agens 10/26/22 Press Release Van Agens 10/26/22 Promontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium Read More Press Release Van Agens 10/20/22 Press Release Van Agens 10/20/22 Promontory Therapeutics Receives U.S. Patent for Therapeutic Applications of PT-112 as an Immuno-Modulatory Agent Read More Press Release Van Agens 9/13/22 Press Release Van Agens 9/13/22 Promontory Therapeutics Appoints Two Experienced Executives to Its Core Management Team Read More Press Release Van Agens 8/11/22 Press Release Van Agens 8/11/22 Promontory Therapeutics Announces Peer-Reviewed Publication in Cancers of Selective Effects of PT-112 in Cancer Cell Models Driven by Mitochondrial Dysfunction Read More Van Agens 6/16/22 Van Agens 6/16/22 Delimiting and delivering: Promontory co-founder 'can't hire fast enough' as small biotech expands vision Read More Press Release Van Agens 6/8/22 Press Release Van Agens 6/8/22 Promontory Therapeutics Announces Peer Reviewed Publication of First-in-Human Clinical Trial of PT-112 in The Lancet's eClinicalMedicine Read More Older Posts
Press Release Van Agens 3/8/24 Press Release Van Agens 3/8/24 Promontory Therapeutics Completes Enrollment of Phase 2 Trial of PT-112 in Late-Line Patients with Metastatic Castration-Resistant Prostate Cancer Read More
Press Release Van Agens 11/4/23 Press Release Van Agens 11/4/23 Promontory Therapeutics Presents Data on Molecular Mechanisms of PT-112's Immunogenic Effects Read More
Press Release Van Agens 10/14/23 Press Release Van Agens 10/14/23 Promontory Therapeutics Presents Data on the Molecular Effects of PT-112 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Read More
Press Release Van Agens 10/5/23 Press Release Van Agens 10/5/23 Promontory Therapeutics Announces Early Phase 2 Clinical Trial Data From the National Cancer Institute, Demonstrating PT-112's Immune Activation in Thymic Epithelial Tumors Read More
Press Release Van Agens 9/29/23 Press Release Van Agens 9/29/23 Promontory Therapeutics Selected as the First International Biotech Company Member of the Paris-Saclay Cancer Cluster Read More
Press Release Van Agens 7/27/23 Press Release Van Agens 7/27/23 The Galien Foundation Announces 2023 Prix Galien USA Nominees for "Best Digital Health Solution," "Best Medical Technology," "Incubators, Accelerators and Equity," and "Best Startup" Read More
Press Release Van Agens 7/20/23 Press Release Van Agens 7/20/23 Promontory Therapeutics Expands Phase 2 Trial of PT-112 in Metastatic Castrate-Resistant Prostate Cancer to France Read More
Press Release Van Agens 6/2/23 Press Release Van Agens 6/2/23 Promontory Therapeutics Announces Preliminary Data from the National Cancer Institute Phase 2 Clinical Trial of PT-112 in Thymoma and Thymic Carcinoma at 2023 ASCO Annual Meeting Read More
Press Release Van Agens 5/31/23 Press Release Van Agens 5/31/23 Promontory Therapeutics to Participate in Business Development Strategies Panel at the Sachs 9th Annual Immuno-Oncology Innovation Forum Read More
Press Release Van Agens 2/16/23 Press Release Van Agens 2/16/23 Promontory Therapeutics Presents Phase 2 Trial in Progress for PT-112 in Prostate Cancer at 2023 ASCO Genitourinary Cancers Symposium Read More
Press Release Van Agens 12/8/22 Press Release Van Agens 12/8/22 Promontory Therapeutics Presents Safety and Efficacy Data of PT-112 in Combination with PD-L1 Inhibition in Treatment of Advanced Non-Small Cell Lung Cancer at ESMO I-O 2022 Read More
Press Release Van Agens 11/28/22 Press Release Van Agens 11/28/22 Promontory Therapeutics Appoints Stan Musial as Chief Financial Officer Read More
Press Release Van Agens 11/11/22 Press Release Van Agens 11/11/22 Promontory Therapeutics Presents on the Immunological Effects of PT-112 in Cancer Cell Mitochondria at SITC 2022 Read More
Press Release Van Agens 11/3/22 Press Release Van Agens 11/3/22 Promontory Therapeutics Awarded “Cancer Immunology Solution of the Year” in 2022 BioTech Breakthrough Awards Program Read More
Press Release Van Agens 10/26/22 Press Release Van Agens 10/26/22 Promontory Therapeutics Reports PT-112's Effects on Human Prostate Cancer Cell Mitochondria at the 34th EORTC-NCI-AACR Symposium Read More
Press Release Van Agens 10/20/22 Press Release Van Agens 10/20/22 Promontory Therapeutics Receives U.S. Patent for Therapeutic Applications of PT-112 as an Immuno-Modulatory Agent Read More
Press Release Van Agens 9/13/22 Press Release Van Agens 9/13/22 Promontory Therapeutics Appoints Two Experienced Executives to Its Core Management Team Read More
Press Release Van Agens 8/11/22 Press Release Van Agens 8/11/22 Promontory Therapeutics Announces Peer-Reviewed Publication in Cancers of Selective Effects of PT-112 in Cancer Cell Models Driven by Mitochondrial Dysfunction Read More
Van Agens 6/16/22 Van Agens 6/16/22 Delimiting and delivering: Promontory co-founder 'can't hire fast enough' as small biotech expands vision Read More
Press Release Van Agens 6/8/22 Press Release Van Agens 6/8/22 Promontory Therapeutics Announces Peer Reviewed Publication of First-in-Human Clinical Trial of PT-112 in The Lancet's eClinicalMedicine Read More
